Buscar

Estamos realizando la búsqueda. Por favor, espere...

Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients with relapsed/refractory multiple myeloma (RRMM): tesults trom the CC-92480-MM-002 trial

Abstract: Results: As of 20 March 2023, 28 patients received MeziVd, 38 MeziVd-1.0 mg, and 27 MeziKd. Across all cohorts, 65.8-88.9% patients were IMiD agent-refractory, 18.4-51.9% proteasome inhibitor (PI)-refractory, and 36.8-74.1% anti CD38 monoclonal antibody (mAb)-refractory; median follow-up was 10.8-13.2 months. The most frequent grade 3-4 treatmentemergent adverse events (TEAEs) were neutropenia (35.7%) and thrombocytopenia (21.4%) with MeziVd; neutropenia (57.9%) and all infections (34.2%) with MeziVd-1.0 mg; and neutropenia (40.7%) and all infections (29.6%) with MeziKd. Excluding all infections, grade 3-4 non-hematologic TEAEs were low. Overall response rate was 75.0% (MeziVd), 84.2% (MeziVd-1.0 mg), and 85.2% (MeziKd). In the MeziVd-1.0 mg cohort, 2 patients were minimal residual disease-negative (10-4 threshold). Median time to response was 1.38 (0.7-3.3), 0.89 (0.7-2.4), and 0.95 (0.9-5.1) months in the MeziVd, MeziVd-1.0 mg, and MeziKd cohorts, respectively. Median duration of response was 10.4 and 11.9 months in the MeziVd and MeziKd cohorts, respectively, and not reached in the MeziVd-1.0 mg cohort. MEZI showed pharmacodynamic activity with BORT/CFZ at all doses; 1.0 mg induced the greatest substrate degradation and T-cell proliferation.

 Editorial: Elsevier

 Año de publicación: 2024

 Nº de páginas: 1

 Tipo de publicación: Comunicación a Congreso

 DOI: 10.1016/S2152-2650(24)01697-5

 ISSN: 2152-2650,2152-2669

 Url de la publicación: https://doi.org/10.1016/S2152-2650(24)01697-5

Autoría

ORIOL ALBERT

SPANDHU, IRWINDEEP

RAAB, MARC S.

WKHITE, DARRELL

LEBLANC, RICHARD

RAJE, NOOPUR

FACON, THIERRY

RODRÍGUEZ, CÉSAR

WAESCH, RALPH

AMATANGELO, MIACHAEL

ZHOU, ZEHUA

WANG, YUE

CIVARDI, TIZIANA

PHARM, PHILLIP KOO

MACIAG, PAULO

ZHU, DANIEL

KATZ, JESSICA

KATZ, PAUL